Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 214.03$. Average daily volumn in 3 months 1.3M. Market cap 37.97B



Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD
Lastest price : 261.69$. Total volume : 1.56M. Market state POST
Click reload if you want to check the lastest price on market!!!

Biogen Inc. (BIIB)
Last Price
261.69$
Change
-5.76
Volume
1.56M

Previous Close267.45
Open265.28
Day Range257.55-266.43
Bid261.52 x 1.2k
Ask261.65 x 1.2k
Volume1.56M
Average Volume1.3M
Market Cap37.97B
Beta0.42
52 Week Range187.16-290.76
Trailing P/E18.68
Foward P/E16.65
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Biogen Inc.'s financial reports the company's revenue in 2021 were 10.98B an decrease(-23.08%) over the years 2020 revenue that were of 13.44B. In 2021 the company's total earnings were 1.56B while total earnings in 2020 were 4B(-75%).


Loading ...



Organization

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Market Cap:
37.97B
Revenue:
10.98B
Total Assets:
23.88B
Total Cash:
2.26B


News about "Biogen Inc."

us-supreme-court-turns-away-biogen-bid-to-reinstate-ms-drug-patent-image

U.S. Supreme Court turns away Biogen bid to reinstate MS drug patent

Source from : Reuters - 2 days ago

The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc ...See details»


us-apex-court-declines-biogen-incs-bid-to-reinstate-multiple-sclerosis-drug-image

US Apex Court declines Biogen Incโ€™s bid to reinstate multiple sclerosis drug

Source from : The Financial Express on MSN - 2 days ago

Tecfidera is still one of Cambridge, Massachusetts-based Biogen's best-selling drugs. But reportedly, the company's revenues from it have dropped because of generic competition.See details»


five-questions-around-biogen-in-wake-of-the-new-alzheimers-drug-data-image

Five questions around Biogen in wake of the new Alzheimer's drug data

Source from : The Business Journals - 6 days ago

Biogen has spent much of the year shedding assets following the disastrous rollout of its first Alzheimer's disease drug. Will its new Alzheimer's drug turn things around and allow the drugmaker to ...See details»


Mega Markets broker Reveals That Biogen Stock Explodes Higher After Potential 'Mega Blockbuster' Alzheimer's Drug Study!

Source from : MarketWatch - 2 days ago

This news has sent Biogen shares soaring as investors bet that the company is on the cusp of a breakthrough in treating this devastating disease. With no cure currently available, any progress in ...See details»


1122-shares-in-biogen-inc-nasdaqbiib-purchased-by-sawtooth-solutions-llc-image

1,122 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by Sawtooth Solutions LLC

Source from : Defense World - 2 days ago

Sawtooth Solutions LLC purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB โ€“ Get Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and ...See details»


fy2023-earnings-estimate-for-biogen-inc-nasdaqbiib-issued-by-oppenheimer-image

FY2023 Earnings Estimate for Biogen Inc. (NASDAQ:BIIB) Issued By Oppenheimer

Source from : Defense World - 2 days ago

Stock analysts at Oppenheimer dropped their FY2023 earnings per share (EPS) estimates for shares of Biogen in a research note issued on Wednesday, September 28th. Oppenheimer analyst J. Olson now ...See details»


Biogen shares soar on landmark Alzheimer's data, lift rivals

Source from : Reuters - 7 days ago

Sept 28 (Reuters) - Biogen Inc (BIIB.O) was set to add more than $10 billion to its market capitalization on Wednesday, as a surprise trial success of the experimental Alzheimer's drug it ...See details»


Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments

Source from : Wall Street Journal - 9 days ago

Biogen Inc. agreed to pay $900 million to settle allegations that it paid kickbacks to doctors to induce them to prescribe the companyโ€™s drugs, the Justice Department said Monday. From 2009 to ...See details»


Pharmaceutical company Biogen agrees to pay $900 million to settle kickback claims

Source from : Washington Times - 8 days ago

Whistleblower alleged firm paid health care professionals to prescribe multiple sclerosis medication Pharmaceutical company Biogen Inc. has agreed to pay $900 million to settle allegations that it ...See details»


biogen-stock-soars-on-promising-data-from-late-stage-alzheimers-drug-trial-image

Biogen Stock Soars On Promising Data From Late-Stage Alzheimerโ€™s Drug Trial

Source from : TheStreet on MSN - 7 days ago

โ€œTodayโ€™s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimerโ€™s disease," said Biogen CEO Michel Vounatsos.See details»


biogen-pays-900m-to-settle-doctor-kickback-allegations-image

Biogen pays $900M to settle doctor kickback allegations

Source from : St. Louis Post-Dispatch - 8 days ago

Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors in the form of speakers and consulting fees to persuade ...See details»


Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson's Disease Associated with LRRK2 Pathogenic Mutations

Source from : TMCnet - 2 days ago

Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2; LRRK2 mutations are one of the most common genetic drivers of Parkinsonโ€™s d ...See details»


Biogen finalizes $900 million drug kickback settlement, U.S. says

Source from : AOL - 9 days ago

By Nate Raymond BOSTON (Reuters) -Biogen Inc has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe ...See details»


New Alzheimerโ€™s Drug From Biogen and Eisai Is Just the Beginning

Source from : The Washington Post - 6 days ago

A drug developed by Biogen Inc. and Eisai Co. has achieved a first in Alzheimerโ€™s research: In a large, late-stage trial, lecanemab slowed down the cognitive decline in people with early disease.See details»